Zacks: Analysts Expect Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $245.18 Million

Equities analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to report sales of $245.18 million for the current quarter, according to Zacks. Two analysts have issued estimates for Horizon Pharma’s earnings, with the highest sales estimate coming in at $257.00 million and the lowest estimate coming in at $233.35 million. Horizon Pharma posted sales of $220.86 million in the same quarter last year, which indicates a positive year over year growth rate of 11%. The company is scheduled to announce its next earnings report on Monday, May 14th.

According to Zacks, analysts expect that Horizon Pharma will report full-year sales of $245.18 million for the current fiscal year, with estimates ranging from $1.15 billion to $1.17 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $1.25 billion per share, with estimates ranging from $1.19 billion to $1.30 billion. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Horizon Pharma.

How to Become a New Pot Stock Millionaire

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.07. The company had revenue of $274.22 million during the quarter, compared to analysts’ expectations of $264.48 million. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. Horizon Pharma’s quarterly revenue was down 11.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.64 earnings per share.

A number of equities research analysts have recently issued reports on HZNP shares. Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and boosted their target price for the company from $12.00 to $18.00 in a research report on Friday, January 12th. ValuEngine cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $17.00 price objective on shares of Horizon Pharma in a research report on Wednesday, March 14th. BidaskClub cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, Morgan Stanley upped their price objective on shares of Horizon Pharma from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Horizon Pharma has an average rating of “Buy” and a consensus target price of $18.64.

Shares of Horizon Pharma stock traded down $0.01 during trading on Monday, reaching $13.64. The company’s stock had a trading volume of 1,623,705 shares, compared to its average volume of 1,856,142. The stock has a market cap of $2,251.92, a PE ratio of 11.56, a PEG ratio of 0.58 and a beta of 1.24. Horizon Pharma has a 52 week low of $9.45 and a 52 week high of $16.02. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.54 and a current ratio of 1.63.

Several hedge funds have recently bought and sold shares of the company. William Blair Investment Management LLC lifted its holdings in shares of Horizon Pharma by 12.2% in the fourth quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock worth $128,861,000 after acquiring an additional 958,414 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Horizon Pharma by 18.6% in the third quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock worth $94,254,000 after acquiring an additional 1,167,722 shares during the last quarter. Brandywine Global Investment Management LLC lifted its holdings in shares of Horizon Pharma by 3.7% in the fourth quarter. Brandywine Global Investment Management LLC now owns 4,160,474 shares of the biopharmaceutical company’s stock worth $60,743,000 after acquiring an additional 149,854 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Horizon Pharma by 105.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,279,400 shares of the biopharmaceutical company’s stock worth $33,279,000 after acquiring an additional 1,170,000 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Horizon Pharma by 419.1% in the third quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock worth $26,979,000 after acquiring an additional 1,717,841 shares during the last quarter. 86.54% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $245.18 Million” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3344358/zacks-analysts-expect-horizon-pharma-plc-hznp-will-announce-quarterly-sales-of-245-18-million.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00
Syntel  Trading -0.6% Higher  After Strong Earnings
Syntel Trading -0.6% Higher After Strong Earnings
BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley


Leave a Reply

© 2006-2018 Ticker Report. Google+.